UblituximabStudy to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia

Sponsor:

TG Therapeutics, Inc.

Code:

NCT07680946

Conditions

Schizophrenia

Eligibility Criteria

Sex: All

Age: 18 - 60

Healthy Volunteers: Not accepted

Interventions

Ublituximab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-25. This information was provided to ClinicalTrials.gov by TG Therapeutics, Inc. on 2026-07-21.